| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 989.71M | — |
| Operating expense | — | — |
| Net income | 44.76M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, BM8.F returned +11.3% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +10.3% |
| 1 year | +11.3% |
| 5 years | -20.5% |
| 10 years | -33.6% |
| All-time high | €133.00 (Jul 2015) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in BM8.F would be worth today ›No. BioMarin Pharmaceutical Inc. has not paid a dividend in the past 12 months.
BioMarin Pharmaceutical Inc. is part of the Healthcare sector.
BioMarin Pharmaceutical Inc. has a market cap of 10.84B EUR, based on the latest quote.
BioMarin Pharmaceutical Inc. is expected to report earnings around Oct 26, 2026. That date is an estimate and has not been confirmed by the company.
